<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00847</drugbank-id>
  <drugbank-id>APRD00896</drugbank-id>
  <name>Cysteamine</name>
  <description>Cysteamine is a radiation-protective agent that oxidizes in air to form cystamine. It can be given intravenously or orally to treat radiation sickness. The bitartrate and hydrochloride salt forms are indicated for the treatment of neuropathic cystinosis in patients 6 years old and older. Cysteamine is marketed under several brand names such as Cystaran, Procysbi, and Cystagon.</description>
  <cas-number>60-23-1</cas-number>
  <unii>5UX2SD1KE2</unii>
  <average-mass>77.149</average-mass>
  <monoisotopic-mass>77.029919919</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A1261</ref-id>
        <pubmed-id>11458646</pubmed-id>
        <citation>Lukashin BP, Grebeniuk AN: [Comparative study of the radiation-protective effectiveness of low doses of cysteamine, heparin, and naphtizine in experiments on mice]. Radiats Biol Radioecol. 2001 May-Jun;41(3):310-2.</citation>
      </article>
      <article>
        <ref-id>A1262</ref-id>
        <pubmed-id>19775699</pubmed-id>
        <citation>Dohil R, Fidler M, Gangoiti JA, Kaskel F, Schneider JA, Barshop BA: Twice-daily cysteamine bitartrate therapy for children with cystinosis. J Pediatr. 2010 Jan;156(1):71-75.e1-3. doi: 10.1016/j.jpeds.2009.07.016. Epub .</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Tethuharu Okazaki, Takeo Komukai, Saburo Uchikuga, "Process for preparing cysteamine-S-substituted compounds and derivatives thereof." U.S. Patent US4371472, issued September, 1969.</synthesis-reference>
  <indication>Given intravenously or orally to treat radiation sickness. The bitartrate salts (Cystagon® and Procysbi) have been used for the oral treatment of nephropathic cystinosis and cystinurea. The hydrochloride salt (Cystaran™) is indicated for the treatment of corneal cystine crystal accumulation in cystinosis patients.&#13;
</indication>
  <pharmacodynamics>People born without the ability to metabolize the amino acid cystine suffer from cystinosis, a rare inherited disorder characterized by the deposition and accumulation of cystine crystals throughout the body. These crystals cause considerable damage, particularly in the kidney and eye. Kidney failure can occur by the age of 10 in untreated patients. Cysteamine prevents the accumulation of cystine crystals and is prescribed to prevent further kidney and eye damage. Cysteamine helps to convert cystine into less harmful chemical forms that can be removed from cells.</pharmacodynamics>
  <mechanism-of-action>The free thiol cysteamine depletes cystinotic leukocytes and other cells of cystine, whose accumulation is considered the cause of organ damage in cystinosis. Cysteamine cleaves the disulfide bond with cystine to produce molecules that can escape the metabolic defect in cystinosis and cystinuria.</mechanism-of-action>
  <toxicity>Symptoms of overdose may include convulsions (seizures), increased thirst and unusual tiredness or weakness.</toxicity>
  <metabolism>The metabolism of cysteamine has not yet been determined.</metabolism>
  <absorption>Cystagon® reaches its maximum plasma concentration in about 1.4 hours.&#13;
&#13;
 </absorption>
  <half-life/>
  <protein-binding>Cysteamine has a plasma protein binding of 52% and is mostly bound to albumin. </protein-binding>
  <route-of-elimination/>
  <volume-of-distribution>Cystagon® has a volume of distribution of 156 L.</volume-of-distribution>
  <clearance>The plasma clearance is about 1.2 L/min.</clearance>
  <classification>
    <description>This compound belongs to the class of organic compounds known as alkylthiols. These are organic compounds containing the thiol functional group linked to an alkyl chain.</description>
    <direct-parent>Alkylthiols</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organosulfur compounds</superclass>
    <class>Thiols</class>
    <subclass>Alkylthiols</subclass>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monoalkylamines</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <substituent>Aliphatic acyclic compound</substituent>
    <substituent>Alkylthiol</substituent>
    <substituent>Amine</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Primary aliphatic amine</substituent>
    <substituent>Primary amine</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT000032</drugbank-id>
      <name>Cysteamine bitartrate</name>
      <unii>QO84GZ3TST</unii>
      <cas-number>27761-19-9</cas-number>
      <inchikey>NSKJTUFFDRENDM-UHFFFAOYSA-N</inchikey>
      <average-mass>227.236</average-mass>
      <monoisotopic-mass>227.046357843</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT000033</drugbank-id>
      <name>Cysteamine hydrochloride</name>
      <unii>IF1B771SVB</unii>
      <cas-number>156-57-0</cas-number>
      <inchikey>OGMADIBCHLQMIP-UHFFFAOYSA-N</inchikey>
      <average-mass>113.61</average-mass>
      <monoisotopic-mass>113.006597658</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="">2-amino-1-ethanethiol</synonym>
    <synonym language="english" coder="">2-amino-ethanethiol</synonym>
    <synonym language="english" coder="iupac">2-aminoethanethiol</synonym>
    <synonym language="english" coder="">beta-aminoethanethiol</synonym>
    <synonym language="english" coder="">beta-Mercaptoethylamine</synonym>
    <synonym language="english" coder="usan">Cysteamine</synonym>
    <synonym language="english" coder="">MEA</synonym>
    <synonym language="spanish" coder="inn">Mercaptamina</synonym>
    <synonym language="english" coder="inn">Mercaptamine</synonym>
    <synonym language="latin" coder="inn">Mercaptaminum</synonym>
    <synonym language="english" coder="">Thioethanolamine</synonym>
    <synonym language="english" coder="">β-aminoethylthiol</synonym>
    <synonym language="english" coder="">β-MEA</synonym>
  </synonyms>
  <products>
    <product>
      <name>Cystadrops</name>
      <labeller>Recordati Rare Diseases Canada Inc</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02485605</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-05-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength/>
      <route>Ophthalmic</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Cystagon</name>
      <labeller>Orphan Europe S.A.R.L.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000125</ema-product-code>
      <ema-ma-number>EU/1/97/039/001</ema-ma-number>
      <started-marketing-on>1997-06-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Cystagon</name>
      <labeller>Orphan Europe S.A.R.L.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000125</ema-product-code>
      <ema-ma-number>EU/1/97/039/002</ema-ma-number>
      <started-marketing-on>1997-06-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Cystagon</name>
      <labeller>Orphan Europe S.A.R.L.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000125</ema-product-code>
      <ema-ma-number>EU/1/97/039/003</ema-ma-number>
      <started-marketing-on>1997-06-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Cystagon</name>
      <labeller>Orphan Europe S.A.R.L.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000125</ema-product-code>
      <ema-ma-number>EU/1/97/039/004</ema-ma-number>
      <started-marketing-on>1997-06-23</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Cystagon</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-9040</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>50 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020392</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cystagon</name>
      <labeller>Mylan Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>0378-9045</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2005-04-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA020392</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Cystaran</name>
      <labeller>Leadiant Biosciences, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>54482-020</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2012-12-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>6.5 mg/1mL</strength>
      <route>Ophthalmic</route>
      <fda-application-number>NDA200740</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procysbi</name>
      <labeller>Horizon Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75987-100</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, delayed release pellets</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA203389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procysbi</name>
      <labeller>Horizon Pharma Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>75987-101</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-30</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, delayed release pellets</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA203389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Procysbi</name>
      <labeller>Horizon Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464705</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, delayed release</dosage-form>
      <strength>25 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Procysbi</name>
      <labeller>Horizon Pharma, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02464713</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2017-10-17</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Capsule, delayed release</dosage-form>
      <strength>75 mg</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>PROCYSBI Delayed-release</name>
      <labeller>Raptor Therapeutics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49663-001</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-30</started-marketing-on>
      <ended-marketing-on>2019-02-28</ended-marketing-on>
      <dosage-form>Capsule, delayed release pellets</dosage-form>
      <strength>25 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA203389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>PROCYSBI Delayed-release</name>
      <labeller>Raptor Therapeutics Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>49663-002</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2013-04-30</started-marketing-on>
      <ended-marketing-on>2019-02-28</ended-marketing-on>
      <dosage-form>Capsule, delayed release pellets</dosage-form>
      <strength>75 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA203389</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>PROCYSBI Delayed-release</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>PROCYSBI Delayed-release</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Cystagon</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Cystagon</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Cystagon</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Cystagon</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Cystagon</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Cystagon</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Procysbi</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Procysbi</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Cystaran</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Procysbi</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Procysbi</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
    <mixture>
      <name>Cystadrops</name>
      <ingredients>Cysteamine</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Mylan</name>
      <url>http://www.mylan.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Mylan pharmaceuticals inc</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Cystagon 150 mg capsule</description>
      <cost currency="USD">1.28</cost>
      <unit>capsule</unit>
    </price>
    <price>
      <description>Cystagon 50 mg capsule</description>
      <cost currency="USD">0.44</cost>
      <unit>capsule</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Alimentary Tract and Metabolism</category>
      <mesh-id/>
    </category>
    <category>
      <category>Amines</category>
      <mesh-id>D000588</mesh-id>
    </category>
    <category>
      <category>Amino Acids and Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cystine Depleting Agents</category>
      <mesh-id>D065104</mesh-id>
    </category>
    <category>
      <category>Cystine Disulfide Reduction</category>
      <mesh-id/>
    </category>
    <category>
      <category>EENT Drugs, Miscellaneous</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ethylamines</category>
      <mesh-id>D005021</mesh-id>
    </category>
    <category>
      <category>Mercaptoethylamines</category>
      <mesh-id>D008624</mesh-id>
    </category>
    <category>
      <category>Ophthalmics</category>
      <mesh-id/>
    </category>
    <category>
      <category>Ophthalmologicals</category>
      <mesh-id/>
    </category>
    <category>
      <category>Other Miscellaneous Therapeutic Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sensory Organs</category>
      <mesh-id/>
    </category>
    <category>
      <category>Sulfhydryl Compounds</category>
      <mesh-id>D013438</mesh-id>
    </category>
    <category>
      <category>Sulfur Compounds</category>
      <mesh-id>D013457</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>150 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>150 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>50 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule</form>
      <route>Oral</route>
      <strength>50 mg/1</strength>
    </dosage>
    <dosage>
      <form>Solution</form>
      <route>Ophthalmic</route>
      <strength>6.5 mg/1mL</strength>
    </dosage>
    <dosage>
      <form>Capsule, delayed release</form>
      <route>Oral</route>
      <strength>25 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule, delayed release</form>
      <route>Oral</route>
      <strength>75 mg</strength>
    </dosage>
    <dosage>
      <form>Capsule, delayed release pellets</form>
      <route>Oral</route>
      <strength>25 mg/1</strength>
    </dosage>
    <dosage>
      <form>Capsule, delayed release pellets</form>
      <route>Oral</route>
      <strength>75 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="A16AA04">
      <level code="A16AA">Amino acids and derivatives</level>
      <level code="A16A">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A16">OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</level>
      <level code="A">ALIMENTARY TRACT AND METABOLISM</level>
    </atc-code>
    <atc-code code="S01XA21">
      <level code="S01XA">Other ophthalmologicals</level>
      <level code="S01X">OTHER OPHTHALMOLOGICALS</level>
      <level code="S01">OPHTHALMOLOGICALS</level>
      <level code="S">SENSORY ORGANS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes>
    <ahfs-code>52:92.00</ahfs-code>
    <ahfs-code>92:92.00</ahfs-code>
  </ahfs-codes>
  <pdb-entries>
    <pdb-entry>2y8d</pdb-entry>
    <pdb-entry>3q1l</pdb-entry>
    <pdb-entry>3som</pdb-entry>
    <pdb-entry>4cg4</pdb-entry>
    <pdb-entry>4pa5</pdb-entry>
    <pdb-entry>5apr</pdb-entry>
    <pdb-entry>5ej0</pdb-entry>
  </pdb-entries>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00847.pdf?1369107169</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00847.pdf?1265922746</msds>
  <patents>
    <patent>
      <number>9192590</number>
      <country>United States</country>
      <approved>2015-11-24</approved>
      <expires>2027-07-26</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9198882</number>
      <country>United States</country>
      <approved>2015-12-01</approved>
      <expires>2027-07-26</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>8026284</number>
      <country>United States</country>
      <approved>2011-09-27</approved>
      <expires>2028-03-22</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9233077</number>
      <country>United States</country>
      <approved>2016-01-12</approved>
      <expires>2034-12-17</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9173851</number>
      <country>United States</country>
      <approved>2015-11-03</approved>
      <expires>2034-12-17</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9925158</number>
      <country>United States</country>
      <approved>2018-03-27</approved>
      <expires>2027-01-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9925157</number>
      <country>United States</country>
      <approved>2018-03-27</approved>
      <expires>2027-01-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9925156</number>
      <country>United States</country>
      <approved>2018-03-27</approved>
      <expires>2027-01-26</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10143665</number>
      <country>United States</country>
      <approved>2018-12-04</approved>
      <expires>2036-08-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>10328037</number>
      <country>United States</country>
      <approved>2019-06-25</approved>
      <expires>2036-08-16</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions>
    <food-interaction>Avoid administration of delayed release cysteamine less than 30 minutes before and within 2 hours after ingesting food due to decreased bioavailability of cysteamine.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB01370</drugbank-id>
      <name>Aluminium</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Aluminium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01377</drugbank-id>
      <name>Magnesium oxide</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Magnesium oxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01390</drugbank-id>
      <name>Sodium bicarbonate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Sodium bicarbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06723</drugbank-id>
      <name>Aluminum hydroxide</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Aluminum hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06724</drugbank-id>
      <name>Calcium carbonate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Calcium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08938</drugbank-id>
      <name>Magaldrate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Magaldrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09104</drugbank-id>
      <name>Magnesium hydroxide</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Magnesium hydroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09281</drugbank-id>
      <name>Magnesium trisilicate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Magnesium trisilicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09481</drugbank-id>
      <name>Magnesium carbonate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Magnesium carbonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13209</drugbank-id>
      <name>Bismuth subnitrate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Bismuth subnitrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13249</drugbank-id>
      <name>Magnesium silicate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Magnesium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13280</drugbank-id>
      <name>Aluminium acetoacetate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Aluminium acetoacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13322</drugbank-id>
      <name>Hydrotalcite</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Hydrotalcite.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13486</drugbank-id>
      <name>Magnesium peroxide</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Magnesium peroxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13595</drugbank-id>
      <name>Almasilate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Almasilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13626</drugbank-id>
      <name>Aluminium glycinate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Aluminium glycinate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13650</drugbank-id>
      <name>Aloglutamol</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Aloglutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13829</drugbank-id>
      <name>Calcium silicate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Calcium silicate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14517</drugbank-id>
      <name>Aluminium phosphate</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Aluminium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00213</drugbank-id>
      <name>Pantoprazole</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Pantoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00736</drugbank-id>
      <name>Esomeprazole</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Esomeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Rabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05351</drugbank-id>
      <name>Dexlansoprazole</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Dexlansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13762</drugbank-id>
      <name>Dexrabeprazole</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Dexrabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15246</drugbank-id>
      <name>Salvianolic acid A</name>
      <description>The bioavailability of Cysteamine can be decreased when combined with Salvianolic acid A.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>Olanzapine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>Cimetidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00585</drugbank-id>
      <name>Nizatidine</name>
      <description>Nizatidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>Ranitidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00927</drugbank-id>
      <name>Famotidine</name>
      <description>Famotidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00940</drugbank-id>
      <name>Methantheline</name>
      <description>Methantheline can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>Promethazine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>Doxepin can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06216</drugbank-id>
      <name>Asenapine</name>
      <description>Asenapine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08805</drugbank-id>
      <name>Metiamide</name>
      <description>Metiamide can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08806</drugbank-id>
      <name>Roxatidine acetate</name>
      <description>Roxatidine acetate can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12770</drugbank-id>
      <name>Lafutidine</name>
      <description>Lafutidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12884</drugbank-id>
      <name>Lavoltidine</name>
      <description>Lavoltidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13760</drugbank-id>
      <name>Niperotidine</name>
      <description>Niperotidine can cause an increase in the absorption of Cysteamine resulting in an increased serum concentration and potentially a worsening of adverse effects.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00898</drugbank-id>
      <name>Ethanol</name>
      <description>The risk or severity of adverse effects can be increased when Ethanol is combined with Cysteamine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.01</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-0.52</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>2.35e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>-0.42</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>2-aminoethane-1-thiol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>cysteamine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>77.149</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>77.029919919</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NCCS</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C2H7NS</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C2H7NS/c3-1-2-4/h4H,1-3H2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>UFULAYFCSOUIOV-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>26.02</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>22.39</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>8.65</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>9.42</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>10.4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Freely soluble in water.</value>
      <source>From The Merck Index.</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>98 °C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.1</value>
      <source/>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22871</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>17141</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>6058</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46507730</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C01678</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D03634</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>5834</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>7968</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA449171</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>DHL</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Therapeutic Targets Database</resource>
      <identifier>DAP001297</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Cysteamine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL602</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cystagon-drug.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/cysteamine.html</url>
    </external-link>
  </external-links>
  <pathways>
    <pathway>
      <smpdb-id>SMP0000021</smpdb-id>
      <name>Taurine and Hypotaurine Metabolism</name>
      <category>metabolic</category>
      <drugs>
        <drug>
          <drugbank-id>DB00114</drugbank-id>
          <name>Pyridoxal phosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB00151</drugbank-id>
          <name>L-Cysteine</name>
        </drug>
        <drug>
          <drugbank-id>DB00847</drugbank-id>
          <name>Cysteamine</name>
        </drug>
        <drug>
          <drugbank-id>DB01592</drugbank-id>
          <name>Iron</name>
        </drug>
        <drug>
          <drugbank-id>DB01956</drugbank-id>
          <name>Taurine</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>Q16878</uniprot-id>
        <uniprot-id>Q96SZ5</uniprot-id>
        <uniprot-id>Q9Y600</uniprot-id>
        <uniprot-id>Q99259</uniprot-id>
        <uniprot-id>Q6P531</uniprot-id>
      </enzymes>
    </pathway>
    <pathway>
      <smpdb-id>SMP0000027</smpdb-id>
      <name>Pantothenate and CoA Biosynthesis</name>
      <category>metabolic</category>
      <drugs>
        <drug>
          <drugbank-id>DB00131</drugbank-id>
          <name>Adenosine phosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB00151</drugbank-id>
          <name>L-Cysteine</name>
        </drug>
        <drug>
          <drugbank-id>DB00171</drugbank-id>
          <name>ATP</name>
        </drug>
        <drug>
          <drugbank-id>DB00847</drugbank-id>
          <name>Cysteamine</name>
        </drug>
        <drug>
          <drugbank-id>DB01373</drugbank-id>
          <name>Calcium</name>
        </drug>
        <drug>
          <drugbank-id>DB01783</drugbank-id>
          <name>Pantothenic acid</name>
        </drug>
        <drug>
          <drugbank-id>DB02431</drugbank-id>
          <name>Cytidine-5'-Triphosphate</name>
        </drug>
        <drug>
          <drugbank-id>DB03247</drugbank-id>
          <name>Flavin mononucleotide</name>
        </drug>
        <drug>
          <drugbank-id>DB04160</drugbank-id>
          <name>Pyrophosphoric acid</name>
        </drug>
      </drugs>
      <enzymes>
        <uniprot-id>O95497</uniprot-id>
        <uniprot-id>Q8TE04</uniprot-id>
        <uniprot-id>Q9HAB8</uniprot-id>
        <uniprot-id>Q96CD2</uniprot-id>
        <uniprot-id>Q13057</uniprot-id>
        <uniprot-id>P22413</uniprot-id>
      </enzymes>
    </pathway>
  </pathways>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0004827</id>
      <name>Cystine</name>
      <organism>Humans</organism>
      <actions>
        <action>cleavage</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17147</ref-id>
            <pubmed-id>21147534</pubmed-id>
            <citation>Omran Z, Kay G, Di Salvo A, Knott RM, Cairns D: PEGylated derivatives of cystamine as enhanced treatments for nephropathic cystinosis. Bioorg Med Chem Lett. 2011 Jan 1;21(1):45-7. doi: 10.1016/j.bmcl.2010.11.085. Epub 2010 Nov 21.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
    </target>
    <target position="2">
      <id>BE0001070</id>
      <name>Somatostatin</name>
      <organism>Humans</organism>
      <actions>
        <action>binder</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A12145</ref-id>
            <pubmed-id>2653642</pubmed-id>
            <citation>Ahren B, Bottcher G, Ekman R, Sundler F: Cysteamine and the endocrine pancreas: immunocytochemical, immunochemical, and functional aspects. Cell Tissue Res. 1989 Apr;256(1):159-66.</citation>
          </article>
          <article>
            <ref-id>A12146</ref-id>
            <pubmed-id>2901134</pubmed-id>
            <citation>McIntosh CH, Bakich V, Bokenfohr K, DiScala-Guenot D, Kwok YN, Brown JC: Cysteamine-induced reduction in gastrointestinal somatostatin: evidence for a region-specific loss in immunoreactivity. Regul Pept. 1988 Jun;21(3-4):205-18.</citation>
          </article>
          <article>
            <ref-id>A12147</ref-id>
            <pubmed-id>4080089</pubmed-id>
            <citation>Terry LC, Craig R: Cysteamine effects on monoamines, dopamine-beta-hydroxylase and the hypothalamic-pituitary axis. Neuroendocrinology. 1985 Dec;41(6):467-75.</citation>
          </article>
          <article>
            <ref-id>A12148</ref-id>
            <pubmed-id>6142843</pubmed-id>
            <citation>McIntosh C, Bakich V, Trotter T, Kwok YN, Nishimura E, Pederson R, Brown J: Effect of cysteamine on secretion of gastrin and somatostatin from the rat stomach. Gastroenterology. 1984 May;86(5 Pt 1):834-8.</citation>
          </article>
          <article>
            <ref-id>A9</ref-id>
            <pubmed-id>11752352</pubmed-id>
            <citation>Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P61278" source="Swiss-Prot">
        <name>Somatostatin</name>
        <general-function>Hormone activity</general-function>
        <specific-function>Somatostatin inhibits the release of somatotropin.</specific-function>
        <gene-name>SST</gene-name>
        <locus>3q28</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-24</signal-regions>
        <theoretical-pi>5.18</theoretical-pi>
        <molecular-weight>12735.395</molecular-weight>
        <chromosome-location>3</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11329</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>SST</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J00306</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>338288</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P61278</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>SMS_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Growth hormone release-inhibiting factor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010750|Somatostatin
MLSCRLQCALAALSIVLALGCVTGAPSDPRLRQFLQKSLAAAAGKQELAKYFLAELLSEP
NQTENDALEPEDLSQAAEQDEMRLELQRSANSNPAMAPRERKAGCKNFFWKTFTSC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010751|Somatostatin (SST)
ATGCTGTCCTGCCGCCTCCAGTGCGCGCTGGCTGCGCTGTCCATCGTCCTGGCCCTGGGC
TGTGTCACCGGCGCTCCCTCGGACCCCAGACTCCGTCAGTTTCTGCAGAAGTCCCTGGCT
GCTGCCGCGGGGAAGCAGGAACTGGCCAAGTACTTCTTGGCAGAGCTGCTGTCTGAACCC
AACCAGACGGAGAATGATGCCCTGGAACCTGAAGATCTGTCCCAGGCTGCTGAGCAGGAT
GAAATGAGGCTTGAGCTGCAGAGATCTGCTAACTCAAACCCGGCTATGGCACCCCGAGAA
CGCAAAGCTGGCTGCAAGAATTTCTTCTGGAAGACTTTCACATCCTGTTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03002</identifier>
            <name>Somatostatin</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuronal cell body</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>hormone activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell-cell signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>digestion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hormone-mediated apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hyperosmotic response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cell migration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to acidic pH</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amino acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to heat</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to steroid hormone</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0002419</id>
      <name>Neuropeptide Y receptor type 2</name>
      <organism>Humans</organism>
      <actions>
        <action>other/unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A15729</ref-id>
            <pubmed-id>1314592</pubmed-id>
            <citation>Li W, Hexum TD: Cysteamine selectively enhances neuropeptide Y2 receptor binding activity. Biochem Biophys Res Commun. 1992 Apr 15;184(1):380-6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P49146" source="Swiss-Prot">
        <name>Neuropeptide Y receptor type 2</name>
        <general-function>Receptor activity</general-function>
        <specific-function>Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PYY &gt; NPY &gt; PYY (3-36) &gt; NPY (2-36) &gt; [Ile-31, Gln-34] PP &gt; [Leu-31, Pro-34] NPY &gt; PP, [Pro-34] PYY and NPY free acid.</specific-function>
        <gene-name>NPY2R</gene-name>
        <locus>4q31</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>52-72
87-107
125-145
166-186
217-237
269-289
305-325</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.26</theoretical-pi>
        <molecular-weight>42730.69</molecular-weight>
        <chromosome-location>4</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7957</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>NPY2R</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U36269</identifier>
          </external-identifier>
          <external-identifier>
            <resource>IUPHAR</resource>
            <identifier>306</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>306</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P49146</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NPY2R_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>NPY-Y2 receptor</synonym>
          <synonym>NPY2-R</synonym>
          <synonym>Y2 receptor</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0019283|Neuropeptide Y receptor type 2
MGPIGAEADENQTVEEMKVEQYGPQTTPRGELVPDPEPELIDSTKLIEVQVVLILAYCSI
ILLGVIGNSLVIHVVIKFKSMRTVTNFFIANLAVADLLVNTLCLPFTLTYTLMGEWKMGP
VLCHLVPYAQGLAVQVSTITLTVIALDRHRCIVYHLESKISKRISFLIIGLAWGISALLA
SPLAIFREYSLIEIIPDFEIVACTEKWPGEEKSIYGTVYSLSSLLILYVLPLGIISFSYT
RIWSKLKNHVSPGAANDHYHQRRQKTTKMLVCVVVVFAVSWLPLHAFQLAVDIDSQVLDL
KEYKLIFTVFHIIAMCSTFANPLLYGWMNSNYRKAFLSAFRCEQRLDAIHSEVSVTFKAK
KNLEVRKNSGPNDSFTEATNV</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019284|Neuropeptide Y receptor type 2 (NPY2R)
ATGGGTCCAATAGGTGCAGAGGCTGATGAGAACCAGACAGTGGAAGAAATGAAGGTGGAA
CAATACGGGCCACAAACAACTCCTAGAGGTGAACTGGTCCCTGACCCTGAGCCAGAGCTT
ATAGATAGTACCAAGCTGATTGAGGTACAAGTTGTTCTCATATTGGCCTACTGCTCCATC
ATCTTGCTTGGGGTAATTGGCAACTCCTTGGTGATCCATGTGGTGATCAAATTCAAGAGC
ATGCGCACAGTAACCAACTTTTTCATTGCCAATCTGGCTGTGGCAGATCTTTTGGTGAAC
ACTCTGTGTCTACCGTTCACTCTTACCTATACCTTAATGGGGGAGTGGAAAATGGGTCCT
GTCCTGTGCCACCTGGTGCCCTATGCCCAGGGCCTGGCAGTACAAGTATCCACAATCACC
TTGACAGTAATTGCCCTGGACCGGCACAGGTGCATCGTCTACCACCTAGAGAGCAAGATC
TCCAAGCGAATCAGCTTCCTGATTATTGGCTTGGCCTGGGGCATCAGTGCCCTGCTGGCA
AGTCCCCTGGCCATCTTCCGGGAGTATTCGCTGATTGAGATCATCCCGGACTTTGAGATT
GTGGCCTGTACTGAAAAGTGGCCTGGCGAGGAGAAGAGCATCTATGGCACTGTCTATAGT
CTTTCTTCCTTGTTGATCTTGTATGTTTTGCCTCTGGGCATTATATCATTTTCCTACACT
CGCATTTGGAGTAAATTGAAGAACCATGTCAGTCCTGGAGCTGCAAATGACCACTACCAT
CAGCGAAGGCAAAAAACCACCAAAATGCTGGTGTGTGTGGTGGTGGTGTTTGCGGTCAGC
TGGCTGCCTCTCCATGCCTTCCAGCTTGCCGTTGACATTGACAGCCAGGTCCTGGACCTG
AAGGAGTACAAACTCATCTTCACAGTGTTCCACATCATCGCCATGTGCTCCACTTTTGCC
AATCCCCTTCTCTATGGCTGGATGAACAGCAACTACAGAAAGGCTTTCCTCTCGGCCTTC
CGCTGTGAGCAGCGGTTGGATGCCATTCACTCTGAGGTGTCCGTGACATTCAAGGCTAAA
AAGAACCTGGAGGTCAGAAAGAACAGTGGCCCCAATGACTCTTTCACAGAGGCTACCAAT
GTCTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00001</identifier>
            <name>7tm_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nonmotile primary cilium</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium channel regulator activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>neuropeptide Y receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptide YY receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>behavioral fear response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cardiac left ventricle morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>feeding behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>locomotory behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cAMP biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of excitatory postsynaptic potential</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of feeding behavior</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of neurological system process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neuropeptide signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nitric oxide mediated signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>outflow tract morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell-substrate adhesion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of circadian sleep/wake cycle, non-REM sleep</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytosolic calcium ion concentration</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dopamine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of peptide secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="4">
      <id>BE0001075</id>
      <name>Myeloperoxidase</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17696</ref-id>
            <pubmed-id>2852004</pubmed-id>
            <citation>Svensson BE: Abilities of peroxidases to catalyse peroxidase-oxidase oxidation of thiols. Biochem J. 1988 Dec 15;256(3):757-62.</citation>
          </article>
          <article>
            <ref-id>A17697</ref-id>
            <pubmed-id>8381104</pubmed-id>
            <citation>Svensson BE, Graslund A, Strom G, Moldeus P: Thiols as peroxidase substrates. Free Radic Biol Med. 1993 Feb;14(2):167-75.</citation>
          </article>
          <article>
            <ref-id>A17698</ref-id>
            <pubmed-id>2829860</pubmed-id>
            <citation>Svensson BE, Lindvall S: Myeloperoxidase-oxidase oxidation of cysteamine. Biochem J. 1988 Jan 15;249(2):521-30.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05164" source="Swiss-Prot">
        <name>Myeloperoxidase</name>
        <general-function>Peroxidase activity</general-function>
        <specific-function>Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.</specific-function>
        <gene-name>MPO</gene-name>
        <locus>17q23.1</locus>
        <cellular-location>Lysosome</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-48</signal-regions>
        <theoretical-pi>9.14</theoretical-pi>
        <molecular-weight>83867.71</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7218</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>MPO</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J02694</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189040</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2789</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05164</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PERM_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.11.2.2</synonym>
          <synonym>MPO</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002139|Myeloperoxidase
MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS
LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH
VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC
NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD
QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND
PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL
GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL
REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR
SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE
GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN
AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL
LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS
NSYPRDFVNCSTLPALNLASWREAS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016304|Myeloperoxidase (MPO)
ATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT
GGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG
GCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG
TTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG
CGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC
TACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC
GTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC
ACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC
CAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC
AACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG
GCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC
GGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT
CAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC
CACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC
TGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC
CCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC
GGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC
ATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG
GGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC
AACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG
GCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT
CGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG
AGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG
GACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT
TCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC
GGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA
CCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA
GGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG
AACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG
CTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT
GCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG
CTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC
GACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC
CTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG
GAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC
CGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC
AACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC
TGGAGGGAAGCCTCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03098</identifier>
            <name>An_peroxidase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>azurophil granule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heparin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peroxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to fungus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hypochlorous acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>low-density lipoprotein particle remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of growth of symbiont in host</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>removal of superoxide radicals</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>respiratory burst involved in defense response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to yeast</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>